FDA approval announcements: Attention-grabbing or event-day misspecification?

Loading...
Thumbnail Image
Files
FDA_HHNM_EconLett.pdf(207.27 KB)
Accepted Version
Date
2018-06-25
Authors
Hamill, Philip A.
Hutchinson, Mark C.
Nguyen, Quang Minh Nhi
Mulcahy, Mark
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier B.V.
Research Projects
Organizational Units
Journal Issue
Abstract
The attention-grabbing hypothesis has been offered as a behavioural explanation for post-event abnormal returns for FDA drug approval announcements for NYSE listed firms. We show that when event-day mis-specification is accounted for, the market reaction is centred on the event-day and that the increase in firm value is driven by after-market-close approval announcements.
Description
Keywords
Research and Development , FDA , Attention-grabbing , Pharmaceuticals , Event study
Citation
Hamill, P. A., Hutchinson, M. C., Nguyen, Q. M. N. and Mulcahy, M. (2018) 'FDA approval announcements: attention-grabbing or event-day misspecification?', Economics Letters, 170, pp. 171-174. doi: 10.1016/j.econlet.2018.06.024